| Trial ID: | L2109 |
| Source ID: | NCT02122731
|
| Associated Drug: |
Amiloride
|
| Title: |
Amiloride for Resistant Hypertension
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hypertension|Type 2 Diabetes Mellitus|Microalbuminuria
|
| Interventions: |
DRUG: Amiloride
|
| Outcome Measures: |
Primary: average daytime systolic and diastolic blood pressure, ambulatory blood pressure monitoring was performed at baseline and after 8 weeks intervention with amiloride, 8 weeks | Secondary: Urinary albumin excretion, Urine albumin was measured at baseline and after 8 weeks of amiloride treatment., after 8 weeks|plasma potassium, plasma potassium tend to increase during amiloride treatment, after 4 and 8 weeks|urinary urokinase plasminogen activator (uPA) activity, uPA exist in urine where it cleaves plasminogen to plasmin. uPA is possible secreted fra the tubulus cells, At baseline and after 8 weeks of amiloride treatment|urine plasminogen and plasmin, U-plasminogen is filtered to urine in patients with microalbuminuria. In urine plasminogen is activated to plasmin by urokinase plasminogen activator.Plasmin activates the epithelial sodium channel., at baseline and after 8 weeks of amiloride treatment
|
| Sponsor/Collaborators: |
Sponsor: Ib Abildgaard Jacobsen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-11
|
| Completion Date: |
2012-08
|
| Results First Posted: |
|
| Last Update Posted: |
2014-04-24
|
| Locations: |
Sydvestjysk Hospital, Esbjerg, Esbjerg, Denmark|Sygehus Lillebaelt., Fredericia, Denmark|Steno Diabetes Center, Gentofte, Denmark|Odense University Hospital, Department of Endocrinology, Odense, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT02122731
|
